Nectar Lifescience Peer Comparison

NSE: NECLIFE | BSE: 532649

₹10.34

₹-0.19 (-1.80%)

As on 28-Oct-2026IST

Market cap

₹201 Cr

Revenue (TTM)

₹7 Cr

P/E Ratio

P/B Ratio

0.4

Div. Yield

0 %

Edit

	Nectar Lifescience	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	201	35,540	25,680	17,194	13,276
Revenue (₹ Cr)	7	9,683	2,372	2,590	1,170
Net Profit (₹ Cr)	-245.06	1,018.97	497.77	603.02	279.64
Net Margin (%)	82.84	10.47	20.72	22.63	22.94
RoE (%)	-1.21	21.30	28.49	19.61	13.92
Price to Earnings	--	35.14	51.59	28.51	47.00
Price-To-Book	0.36	6.79	12.71	4.93	6.40

Income Statement (₹ Cr)

	Nectar Lifescience	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	7.44	9,683.45	2,371.81	2,590.40	1,170.41
Total Income	17.34	9,730.84	2,402.61	2,664.23	1,218.73
Total Expenditure	94.20	7,739.53	1,608.91	1,753.71	766.14
EBITDA	-86.76	1,943.92	762.90	836.69	404.27
Depreciation	0.46	425.10	98.11	78.88	74.77
EBIT	-87.22	1,518.82	664.79	757.81	329.50
Interest	36.28	148.45	26.33	5.43	0.24
Other Income	9.90	47.39	30.80	73.83	48.32
Exceptional Items	88.15	-27.85	0.00	-25.66	-3.28
Profit before Tax	-25.46	1,389.91	669.26	800.55	374.31
Provision for Tax	-39.82	370.94	171.48	197.53	94.68
Profit after Tax	14.36	1,018.97	497.77	603.02	279.64

	Nectar Lifescience	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	582.30	4,950.03	1,874.47	3,332.13	2,075.76
Minority Interest	0.00	-7.58	0.00	0.00	3.07
Non-Current Liabilities	13.26	723.57	345.47	142.73	53.38
Current Liabilities	26.05	3,912.24	710.20	508.04	201.71
Total Liabilities	621.61	9,514.48	2,930.14	4,157.10	2,231.79

	Nectar Lifescience	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	329.30	3,392.16	1,290.62	1,321.38	980.16
Current Assets	252.97	5,612.10	1,483.13	2,649.36	1,290.68
Total Assets	621.61	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	0.00	1,204.08	196.61	0.00	0.00
Net Current Assets	226.92	1,699.86	772.93	2,141.33	1,088.97
Contingent Liabilities	229.52	258.92	13.18	4.82	3.76

	Nectar Lifescience	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	-348.72	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	1,208.15	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	-766.51	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	92.91	93.92	-56.08	-69.08	11.28

	Nectar Lifescience	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	-4.75	25.25	27.50	24.61	18.04
ROE (%)	-1.21	21.30	28.49	19.61	13.92
ROA (%)	1.08	11.42	19.48	16.31	12.86
EBIT Margin (%)	-1,171.85	15.68	28.03	29.25	28.15
Net Margin (%)	82.84	10.47	20.72	22.63	22.94
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Nectar Lifescience	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	29.44	18.36	78.33	7.93	4.02
EBIT Growth (%)	-5,157.44	30.43	303.07	19.88	-11.95
Net Profit Growth (%)	84,594.12	32.39	182.61	21.66	-12.44
EPS Growth (%)	-94,104.87	36.68	277.72	25.42	-12.06
Book Value Growth (%)	-39.10	11.36	22.95	18.43	11.27

	Nectar Lifescience	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	-14.49	34.42	51.59	27.61	46.60
Price / Book Value	0.36	6.79	12.71	4.93	6.40
Dividend Yield (%)	0.00	0.19	0.17	0.36	0.59
EV/EBITDA	-0.88	18.83	33.45	19.62	31.81
Market Cap (₹ Cr)	--	30,257.56	15,412.11	11,956.86	10,627.92

	Nectar Lifescience	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.00	0.05	0.09	0.00	0.00
Short term debt to equity ratio	--	0.16	--	--	--
Current Ratio	9.71	1.43	2.09	5.21	6.40
Quick Ratio	9.70	0.82	1.37	3.85	4.43
Interest Coverage	0.30	10.36	26.41	148.49	1,593.82

	Nectar Lifescience	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	0.00	26.46	22.82	41.42	35.24
Asset Turnover	0.01	1.09	0.93	0.70	0.54
Receivable days	--	88.68	77.32	144.58	169.86
Inventory Days	--	84.11	80.83	96.67	97.92
Payable days	--	176.65	125.94	135.45	159.68
Cash Conversion Cycle	--	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.